Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Pediatrics

Understanding Your Trisomy 13 Diagnosis

At a Glance

A Trisomy 13 diagnosis does not by itself determine a child’s treatment or outcome. Survival varies widely, so decisions about comfort-focused care, active treatment, or a time-limited intensive-care trial should reflect the child’s heart and brain findings, response to care, and family goals.

Receiving a diagnosis of Trisomy 13 (also known as Patau syndrome) can feel like the world has suddenly stopped. You may be experiencing a whirlwind of shock, grief, and overwhelming fear. It is important to know that these feelings are a natural response to a diagnosis that is both rare and complex [1].

Trisomy 13 occurs when a child has extra genetic material from the 13th chromosome [2]. This extra material disrupts the typical development of many body systems [3]. Because it occurs in only about 1 in 10,000 to 20,000 live births, it is a very rare condition [4][2]. This rarity means that many doctors—even specialists—may only see one or two cases in their entire career. As a result, the information you receive might sometimes be based on older assumptions rather than the most current, individualized approaches to care [1][5].

Moving Beyond the “Lethal” Label

For many years, Trisomy 13 was described in medical textbooks as “uniformly lethal” or “incompatible with life.” Historically, this meant families were often counseled toward comfort-only care, and active treatments were routinely withheld. Today, medical consensus and ethics have shifted [1][6]. While Trisomy 13 is a life-limiting condition with a high rate of early mortality, decisions about treatment are now based on a child’s specific anatomy and the family’s goals, rather than categorically denying care based on the diagnosis alone [1].

Survival statistics vary widely based on the study year, the country, and whether the data includes prenatal diagnoses or only infants admitted to the NICU. For context:

  • Early Infancy: Population registry data from Europe estimated that about 34% of live-born infants survive the first four weeks of life [7]. A separate U.S. inpatient study noted a 58% mortality rate during the initial hospital stay [8].
  • One-Year Survival: Registry data suggests approximately 17% to 20% of children reach their first birthday [7][9].
  • Long-Term Survival: Studies tracking broad populations have found that about 10% to 13% of children survive to age 10 [9][7].
  • Impact of Genetics: A Texas population study grouped children by genetic subtype, estimating a 10-year survival of 4.9% for those with full Trisomy 13, compared to 25% for a combined group of children with mosaic or partial variants [5].

It is vital to understand that population averages cannot predict exactly what will happen for your child. Your child’s individual clinical condition—particularly the structure of their brain and heart—is far more informative than a broad statistic.

A Multisystem Condition

Trisomy 13 affects development in multiple ways. While every child is different, common areas of concern include:

  • The Heart: Population studies note congenital heart defects in about 57% to 76% of cases, while cohorts of infants treated in the NICU see rates upwards of 86% to 92% [2][10].
  • The Brain: Structural differences in the brain are common and often lead to severe developmental and intellectual disabilities [2][11].
  • Craniofacial Features: This can include cleft lip or palate (an opening in the lip or roof of the mouth) or eye abnormalities [2][3].
  • Other Systems: The condition can also affect the kidneys, breathing, feeding, and the number of fingers or toes (polydactyly) [2][12].

Shared Decision-Making

Today, the medical consensus has shifted toward shared decision-making [1][6]. This means you and your medical team work together to evaluate medically reasonable options and create a plan that aligns with your family’s values and your child’s specific health needs.

You may choose a path focused entirely on comfort, or you may pursue active medical interventions, such as heart surgery or respiratory support [1][13]. Some families opt for a “time-limited trial,” where intensive care is provided initially to see how the baby responds before making long-term decisions [14].

It is important to understand that palliative care is not “giving up” and is not exclusive to end-of-life care. It is an extra layer of support that can be provided alongside active medical treatments to ensure your child is comfortable, manage symptoms, and support your family through difficult decisions [15][16][17]. Goals can be revisited over time, and changing your mind as your child’s clinical situation evolves is a normal part of the process.

Common questions in this guide

What is Trisomy 13 syndrome?
Trisomy 13 syndrome, also called Patau syndrome, occurs when a child has extra genetic material from chromosome 13. This can disrupt development of several body systems, including the heart, brain, face, kidneys, breathing, feeding, and limbs.
What can survival look like for a baby with Trisomy 13?
Trisomy 13 is life-limiting, and many affected infants die early, but survival varies among children. Published estimates differ depending on the population studied, so a child’s heart and brain findings, genetic subtype, and response to care are more useful for individual counseling than a population average.
Can a child with Trisomy 13 receive surgery or intensive treatment?
Yes. Treatment decisions are individualized and may include heart surgery, breathing support, or a time-limited trial of intensive care when these options fit the child’s condition and the family’s goals. Other families may choose care focused only on comfort, and both approaches should be discussed with the medical team.
What health problems are common with Trisomy 13?
Common concerns include congenital heart defects and structural differences in the brain. Children may also have cleft lip or palate, eye or kidney abnormalities, breathing or feeding difficulties, and extra fingers or toes.
Is palliative care the same as giving up?
No. Palliative care focuses on comfort, symptom relief, and support for the child and family, and it can be provided at the same time as treatments such as surgery or respiratory support. It can also help families revisit goals as the child’s condition changes.
How should families make care decisions after a Trisomy 13 diagnosis?
Families and clinicians can use shared decision-making, considering the child’s specific heart, brain, and other findings, the expected benefits and burdens of treatment, and the family’s values. Ask about the hospital’s experience with Trisomy 13, available specialists, and whether a time-limited trial could help clarify how the baby responds.

Get notified when new evidence is published on Trisomy 13 syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    Guidance for Caring for Infants and Children With Trisomy 13 and Trisomy 18: Clinical Report.

    Pyle AK, George TN, Cummings JJ, et al.

    Pediatrics 2025; (156(2)) doi:10.1542/peds.2025-072719.

    PMID: 40685149
  2. 2

    Congenital anomalies associated with trisomy 18 or trisomy 13: A registry-based study in 16 European countries, 2000-2011.

    Springett A, Wellesley D, Greenlees R, et al.

    American journal of medical genetics. Part A 2015; (167A(12)):3062-9 doi:10.1002/ajmg.a.37355.

    PMID: 26347425
  3. 3

    Surveillance guidelines for children with trisomy 13.

    Kepple JW, Fishler KP, Peeples ES

    American journal of medical genetics. Part A 2021; (185(5)):1631-1637 doi:10.1002/ajmg.a.62133.

    PMID: 33709620
  4. 4

    Trisomy 13 and 18-Prevalence and mortality-A multi-registry population based analysis.

    Goel N, Morris JK, Tucker D, et al.

    American journal of medical genetics. Part A 2019; (179(12)):2382-2392 doi:10.1002/ajmg.a.61365.

    PMID: 31566869
  5. 5

    Long-Term Survival Among Children With Trisomy 13 and Trisomy 18 by Cytogenetic Status.

    Ludorf KL, Benjamin RH, Shumate CJ, et al.

    JAMA network open 2025; (8(9)):e2529885 doi:10.1001/jamanetworkopen.2025.29885.

    PMID: 40920381
  6. 6

    Medical and Ethical Considerations Related to Viable Fetuses with Trisomy 13 in the 36th Week of Pregnancy--a Review of the Literature.

    Pawelec M, Dżugalik M, Pietras J, et al.

    Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2015; (24(5)):911-21 doi:10.17219/acem/26324.

    PMID: 26768645
  7. 7

    Ten-year survival of children with trisomy 13 or trisomy 18: a multi-registry European cohort study.

    Glinianaia SV, Rankin J, Tan J, et al.

    Archives of disease in childhood 2023; (108(6)):461-467 doi:10.1136/archdischild-2022-325068.

    PMID: 36882305
  8. 8

    Changes in Hospital Care of Newborn Infants with Trisomy 13.

    Ignatz-Hoover AO, Farghaly MAA, Crist A, et al.

    Maternal and child health journal 2025; (29(5)):622-627 doi:10.1007/s10995-025-04072-z.

    PMID: 39987298
  9. 9

    Survival and Surgical Interventions for Children With Trisomy 13 and 18.

    Nelson KE, Rosella LC, Mahant S, Guttmann A

    JAMA 2016; (316(4)):420-8 doi:10.1001/jama.2016.9819.

    PMID: 27458947
  10. 10

    Clinical courses of children with trisomy 13 receiving intensive neonatal and pediatric treatment.

    Nishi E, Takasugi M, Kawamura R, et al.

    American journal of medical genetics. Part A 2018; (176(9)):1941-1949 doi:10.1002/ajmg.a.40350.

    PMID: 30152146
  11. 11

    Prognostic factors, psychomotor development and life of trisomy 13 patients.

    Yamagishi H, Osaka H, Monden Y, Kono Y

    Pediatrics international : official journal of the Japan Pediatric Society 2022; (64(1)):e15369 doi:10.1111/ped.15369.

    PMID: 36168767
  12. 12

    Otolaryngologic Manifestations of Trisomy 13 and Trisomy 18 in Pediatric Patients.

    Benson J, Stewart C, Kenna MA, Shearer AE

    The Laryngoscope 2023; (133(6)):1501-1506 doi:10.1002/lary.30350.

    PMID: 37158261
  13. 13

    Cardiac Interventions for Patients With Trisomy 13 and Trisomy 18: Experience, Ethical Issues, Communication, and the Case for Individualized Family-Centered Care.

    Cleary JP, Janvier A, Farlow B, et al.

    World journal for pediatric & congenital heart surgery 2022; (13(1)):72-76 doi:10.1177/21501351211044132.

    PMID: 34919485
  14. 14

    Shared decision making and the pathways approach in the prenatal and postnatal management of the trisomy 13 and trisomy 18 syndromes.

    Andrews SE, Downey AG, Showalter DS, et al.

    American journal of medical genetics. Part C, Seminars in medical genetics 2016; (172(3)):257-63 doi:10.1002/ajmg.c.31524.

    PMID: 27557275
  15. 15

    A Case Study of Trisomy 13: Balancing Hope and Reality.

    Stafford CO

    Advances in neonatal care : official journal of the National Association of Neonatal Nurses 2015; (15(4)):285-9 doi:10.1097/ANC.0000000000000208.

    PMID: 26225597
  16. 16

    Early assessment of clinical complexity and home care in patients affected by trisomy 13 and 18.

    Zanin A, Patti M, Rosato I, et al.

    European journal of pediatrics 2025; (184(3)):194 doi:10.1007/s00431-025-06020-z.

    PMID: 39937286
  17. 17

    Mixed method study of quality of life for children with trisomy 18 and 13 after cardiac surgery.

    Weaver MS, Birge N, Hsu H, et al.

    Cardiology in the young 2020; (30(2)):231-237 doi:10.1017/S1047951120000013.

    PMID: 31964456

This page is for informational purposes only and does not constitute medical advice. Discuss your child’s specific findings, prognosis, and care choices with the child’s medical team.